Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

Prognostic and Clinicopathological Correlations of Cell Cycle Marker Expressions before and after the Primary Systemic Therapy of Breast Cancer.

Tőkés T, Tőkés AM, Szentmártoni G, Kiszner G, Mühl D, Molnár BÁ, Kulka J, Krenács T, Dank M.

Pathol Oncol Res. 2019 Aug 24. doi: 10.1007/s12253-019-00726-w. [Epub ahead of print]

PMID:
31446607
2.

Influence of mutagenic versus non-mutagenic pre-operative chemotherapy on the immune infiltration of residual breast cancer.

Tőkés AM, Rusz O, Cserni G, Tóth E, Rubovszky G, Tőkés T, Vízkeleti L, Reiniger L, Kószó R, Kahán Z, Kulka J, Donia M, Vörös A, Szallasi Z.

Acta Oncol. 2019 Jul 4:1-9. doi: 10.1080/0284186X.2019.1633015. [Epub ahead of print]

PMID:
31271119
3.

[Evaluation of resection margins following breast conserving surgery for breast cancer. A multicentric retrospective study].

Fakan B, Baranyi E, Horváth R, Kálmán E, Kulka J, Tölgyesi K, Török M, Udvarhelyi N, Zombori T, Cserni G.

Orv Hetil. 2019 Jun;160(26):1036-1044. doi: 10.1556/650.2019.31449. Hungarian.

PMID:
31230468
4.

Dynamic FDG-PET/CT in the Initial Staging of Primary Breast Cancer: Clinicopathological Correlations.

Kajáry K, Lengyel Z, Tőkés AM, Kulka J, Dank M, Tőkés T.

Pathol Oncol Res. 2019 Apr 3. doi: 10.1007/s12253-019-00641-0. [Epub ahead of print]

PMID:
30941738
5.

Corrigendum to: Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.

Diossy M, Reiniger L, Sztupinszki Z, Krzystanek M, Timms KM, Neff C, Solimeno C, Pruss D, Eklund AC, Tóth E, Kiss O, Rusz O, Cserni G, Zombori T, Székely B, Kulka J, Tímár J, Csabai I, Szallasi Z.

Ann Oncol. 2019 Mar 30. pii: mdz081. doi: 10.1093/annonc/mdz081. [Epub ahead of print] No abstract available.

6.

Cyberincivility in the Massive Open Online Course Learning Environment: Data-Mining Study.

De Gagne JC, Manturuk K, Park HK, Conklin JL, Wyman Roth N, Hook BE, Kulka JM.

JMIR Med Educ. 2018 Dec 21;4(2):e12152. doi: 10.2196/12152.

7.

Mindfulness-Based Stress Reduction for Newly Graduated Registered Nurses.

Kulka JM, De Gagne JC, Mullen CK, Robeano K.

Creat Nurs. 2018 Nov;24(4):243-250. doi: 10.1891/1078-4535.24.4.243.

PMID:
30567967
8.

Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer.

Coulson-Gilmer C, Humphries MP, Sundara Rajan S, Droop A, Jackson S, Condon A, Cserni G, Jordan LB, Jones LJ, Kanthan R, Di Benedetto A, Mottolese M, Provenzano E, Kulka J, Shaaban AM, Hanby AM, Speirs V.

J Pathol Clin Res. 2018 Oct;4(4):241-249. doi: 10.1002/cjp2.106. Epub 2018 Aug 23. Erratum in: J Pathol Clin Res. 2019 Jul;5(3):213.

9.

Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study.

O'Loughlin M, Andreu X, Bianchi S, Chemielik E, Cordoba A, Cserni G, Figueiredo P, Floris G, Foschini MP, Heikkilä P, Kulka J, Liepniece-Karele I, Regitnig P, Reiner A, Ryska A, Sapino A, Shalaby A, Stovgaard ES, Quinn C, Walsh EM, Zolota V, Glynn SA, Callagy G.

Breast Cancer Res Treat. 2018 Aug;171(1):1-9. doi: 10.1007/s10549-018-4825-8. Epub 2018 May 17.

PMID:
29774470
10.

LAPTM4B gene copy number gain is associated with inferior response to anthracycline-based chemotherapy in hormone receptor negative breast carcinomas.

Rusz O, Papp O, Vízkeleti L, Molnár BÁ, Bende KC, Lotz G, Ács B, Kahán Z, Székely T, Báthori Á, Szundi C, Kulka J, Szállási Z, Tőkés AM.

Cancer Chemother Pharmacol. 2018 Jul;82(1):139-147. doi: 10.1007/s00280-018-3602-z. Epub 2018 May 16.

PMID:
29770955
11.

The impact of malignant nipple discharge cytology (NDc) in surgical management of breast cancer patients.

Castellano I, Metovic J, Balmativola D, Annaratone L, Rangel N, Vissio E, Arisio R, Macrì L, Pecchioni C, Sarotto I, Montarolo F, Muscarà F, Marchiò C, Cassoni P, Kulka J, Sapino A.

PLoS One. 2017 Aug 14;12(8):e0182073. doi: 10.1371/journal.pone.0182073. eCollection 2017.

12.

AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients.

Bottai G, Raschioni C, Székely B, Di Tommaso L, Szász AM, Losurdo A, Győrffy B, Ács B, Torrisi R, Karachaliou N, Tőkés T, Caruso M, Kulka J, Roncalli M, Santoro A, Mantovani A, Rosell R, Reis-Filho JS, Santarpia L.

NPJ Breast Cancer. 2016 Nov 2;2:16033. doi: 10.1038/npjbcancer.2016.33. eCollection 2016.

13.

PD-1, PD-L1 and CTLA-4 in pregnancy-related - and in early-onset breast cancer: A comparative study.

Ács B, Madaras L, Tőkés AM, Kovács AK, Kovács E, Ozsvári-Vidákovich M, Karászi Á, Birtalan E, Dank M, Szász AM, Kulka J.

Breast. 2017 Oct;35:69-77. doi: 10.1016/j.breast.2017.06.013. Epub 2017 Jun 23.

PMID:
28651116
14.

Erratum: Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.

Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, Rothé F, Rouas G, Nagy ZI, Faragó Z, Tőkés AM, Dank M, Szentmártoni G, Udvarhelyi N, Zoppoli G, Pusztai L, Piccart M, Kulka J, Lambrechts D, Sotiriou C, Desmedt C.

Nat Commun. 2017 Jun 6;8:15759. doi: 10.1038/ncomms15759.

15.

Prognostic impact of macrometastasis linear size in sentinel node biopsy for breast carcinoma.

Foschini MP, Miglio R, Quinn C, Belgio B, Regitnig P, Bianchi S, Nannini R, Buerger H, Kaya H, Illyés I, Kulka J, Wells CA, De Gaetano J, Lipeniece-Karele I, Cserni G.

Eur J Surg Oncol. 2017 Aug;43(8):1421-1427. doi: 10.1016/j.ejso.2017.05.007. Epub 2017 May 17.

PMID:
28576464
16.

Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.

Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, Rothé F, Rouas G, Nagy ZI, Faragó Z, Tőkés AM, Dank M, Szentmártoni G, Udvarhelyi N, Zoppoli G, Pusztai L, Piccart M, Kulka J, Lambrechts D, Sotiriou C, Desmedt C.

Nat Commun. 2017 Apr 20;8:14944. doi: 10.1038/ncomms14944. Erratum in: Nat Commun. 2017 Jun 06;8:15759.

17.

Reproducibility and Prognostic Potential of Ki-67 Proliferation Index when Comparing Digital-Image Analysis with Standard Semi-Quantitative Evaluation in Breast Cancer.

Ács B, Madaras L, Kovács KA, Micsik T, Tőkés AM, Győrffy B, Kulka J, Szász AM.

Pathol Oncol Res. 2018 Jan;24(1):115-127. doi: 10.1007/s12253-017-0220-8. Epub 2017 Apr 11.

PMID:
28401450
18.

Is Regression after Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer Different in Sentinel and Non-sentinel Nodes?

Cserni G, Zombori T, Andreu X, Bianchi S, Regitnig P, Amendoeira I, Balmativola D, Kovács A, Cordoba A, Reiner A, Kulka J, Kaya H, Liepniece-Karele I, Quinn C, Kővári B.

Pathol Oncol Res. 2018 Jan;24(1):167-170. doi: 10.1007/s12253-017-0229-z. Epub 2017 Apr 8.

PMID:
28391512
19.

Characterisation of male breast cancer: a descriptive biomarker study from a large patient series.

Humphries MP, Sundara Rajan S, Honarpisheh H, Cserni G, Dent J, Fulford L, Jordan LB, Jones JL, Kanthan R, Litwiniuk M, Di Benedetto A, Mottolese M, Provenzano E, Shousha S, Stephens M, Kulka J, Ellis IO, Titloye AN, Hanby AM, Shaaban AM, Speirs V.

Sci Rep. 2017 Mar 28;7:45293. doi: 10.1038/srep45293.

20.

Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.

Ács B, Zámbó V, Vízkeleti L, Szász AM, Madaras L, Szentmártoni G, Tőkés T, Molnár BÁ, Molnár IA, Vári-Kakas S, Kulka J, Tőkés AM.

Diagn Pathol. 2017 Feb 21;12(1):20. doi: 10.1186/s13000-017-0608-5.

21.

Comparison of 5 Ki-67 antibodies regarding reproducibility and capacity to predict prognosis in breast cancer: does the antibody matter?

Ács B, Kulka J, Kovács KA, Teleki I, Tőkés AM, Meczker Á, Győrffy B, Madaras L, Krenács T, Szász AM.

Hum Pathol. 2017 Jul;65:31-40. doi: 10.1016/j.humpath.2017.01.011. Epub 2017 Feb 8.

PMID:
28188752
22.

Breast carcinoma subtypes show different patterns of metastatic behavior.

Molnár IA, Molnár BÁ, Vízkeleti L, Fekete K, Tamás J, Deák P, Szundi C, Székely B, Moldvay J, Vári-Kakas S, Szász MA, Ács B, Kulka J, Tőkés AM.

Virchows Arch. 2017 Mar;470(3):275-283. doi: 10.1007/s00428-017-2065-7. Epub 2017 Jan 19.

PMID:
28101678
23.

A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer.

Humphries MP, Sundara Rajan S, Droop A, Suleman CAB, Carbone C, Nilsson C, Honarpisheh H, Cserni G, Dent J, Fulford L, Jordan LB, Jones JL, Kanthan R, Litwiniuk M, Di Benedetto A, Mottolese M, Provenzano E, Shousha S, Stephens M, Walker RA, Kulka J, Ellis IO, Jeffery M, Thygesen HH, Cappelletti V, Daidone MG, Hedenfalk IA, Fjällskog ML, Melisi D, Stead LF, Shaaban AM, Speirs V.

Clin Cancer Res. 2017 May 15;23(10):2575-2583. doi: 10.1158/1078-0432.CCR-16-1952. Epub 2016 Dec 16.

24.

Comparison of immunophenotypes of primary breast carcinomas and multiple corresponding distant metastases: an autopsy study of 25 patients.

Szekely B, Nagy ZI, Farago Z, Kiss O, Lotz G, Kovacs KA, Madaras L, Udvarhelyi N, Dank M, Szentmartoni G, Baranyai Z, Harsanyi L, Tőkés AM, Timar J, Szasz AM, Kulka J.

Clin Exp Metastasis. 2017 Jan;34(1):103-113. doi: 10.1007/s10585-016-9830-x. Epub 2016 Nov 24.

PMID:
27885435
25.

[Pathological diagnosis, work-up and reporting of breast cancer. Recommendations of the 3rd Hungarian Consensus Conference on Breast Cancer].

Cserni G, Kulka J, Francz M, Járay B, Kálmán E, Kovács I, Krenács T, Udvarhelyi N, Vass L.

Magy Onkol. 2016 Sep;60(3):209-28. Epub 2016 Jun 20. Review. Hungarian.

26.

Erratum to: Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.

Green AR, Soria D, Powe DG, Nolan CC, Aleskandarany M, Szász MA, Tőkés AM, Ball GR, Garibaldi JM, Rakha EA, Kulka J, Ellis IO.

Breast Cancer Res Treat. 2016 Aug;159(1):199. No abstract available.

PMID:
27447877
27.

In depth evaluation of the prognostic and predictive utility of PTEN immunohistochemistry in colorectal carcinomas: performance of three antibodies with emphasis on intracellular and intratumoral heterogeneity.

Ágoston EI, Micsik T, Ács B, Fekete K, Hahn O, Baranyai Z, Dede K, Bodoky G, Bursics A, Kulka J, Krenács T, Győrffy B, Harsányi L, Szász AM.

Diagn Pathol. 2016 Jul 8;11(1):61. doi: 10.1186/s13000-016-0508-0.

28.

Opposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancer.

Szendrői A, Szász AM, Kardos M, Tőkés AM, Idan R, Szűcs M, Kulka J, Nyirády P, Szendrői M, Szállási Z, Győrffy B, Tímár J.

Oncotarget. 2016 Jul 5;7(27):42086-42098. doi: 10.18632/oncotarget.9669.

29.

Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.

Green AR, Soria D, Powe DG, Nolan CC, Aleskandarany M, Szász MA, Tőkés AM, Ball GR, Garibaldi JM, Rakha EA, Kulka J, Ellis IO.

Breast Cancer Res Treat. 2016 May;157(1):65-75. doi: 10.1007/s10549-016-3804-1. Epub 2016 Apr 26. Erratum in: Breast Cancer Res Treat. 2016 Aug;159(1):199.

30.
31.

Comparison of Predictive Immunohistochemical Marker Expression of Primary Breast Cancer and Paired Distant Metastasis using Surgical Material: A Practice-Based Study.

Kulka J, Székely B, Lukács LV, Kiss O, Tőkés AM, Vincze E, Turányi E, Fillinger J, Hanzély Z, Arató G, Szendrői M, Győrffy B, Szász AM.

J Histochem Cytochem. 2016 Apr;64(4):256-67. doi: 10.1369/0022155416639013.

32.

Expression of cell cycle markers is predictive of the response to primary systemic therapy of locally advanced breast cancer.

Tőkés T, Tőkés AM, Szentmártoni G, Kiszner G, Madaras L, Kulka J, Krenács T, Dank M.

Virchows Arch. 2016 Jun;468(6):675-86. doi: 10.1007/s00428-016-1925-x. Epub 2016 Mar 30.

PMID:
27026269
33.

Reliability of immunocytochemistry and fluorescence in situ hybridization on fine-needle aspiration cytology samples of breast cancers: A comparative study.

Acs B, Szekely N, Szasz AM, Lotz G, Szekely T, Istok R, Szekely E, Madaras L, Kulka J, Jaray B.

Diagn Cytopathol. 2016 Jun;44(6):466-71. doi: 10.1002/dc.23463. Epub 2016 Mar 16.

PMID:
26990933
34.

Predictive and prognostic value of FDG-PET/CT imaging and different response evaluation criteria after primary systemic therapy of breast cancer.

Tőkés T, Kajáry K, Szentmártoni G, Lengyel Z, Györke T, Torgyík L, Somlai K, Tőkés AM, Kulka J, Dank M.

Breast Cancer. 2017 Jan;24(1):137-146. doi: 10.1007/s12282-016-0685-4. Epub 2016 Mar 15.

PMID:
26979062
35.

Catalog of genetic progression of human cancers: breast cancer.

Desmedt C, Yates L, Kulka J.

Cancer Metastasis Rev. 2016 Mar;35(1):49-62. doi: 10.1007/s10555-016-9609-1. Review.

PMID:
26951551
36.

Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markers.

Cserni G, Wells CA, Kaya H, Regitnig P, Sapino A, Floris G, Decker T, Foschini MP, van Diest PJ, Grabau D, Reiner A, DeGaetano J, Chmielik E, Cordoba A, Andreu X, Zolota V, Charafe-Jauffret E, Ryska A, Varga Z, Weingertner N, Bellocq JP, Liepniece-Karele I, Callagy G, Kulka J, Bürger H, Figueiredo P, Wesseling J, Amendoeira I, Faverly D, Quinn CM, Bianchi S.

Virchows Arch. 2016 Apr;468(4):473-81. doi: 10.1007/s00428-016-1909-x. Epub 2016 Jan 27.

PMID:
26818833
37.

[Clinico-pathologically focused breast cancer research].

Kulka J, Tõkés AM, Madaras L, Kovács A, Ács B, Illyés I, Kiss O, Székely B, Lotz G, Szász MA.

Magy Onkol. 2015 Dec;59(4):286-91. Epub 2015 Oct 12. Hungarian.

38.

BRCA Mutation-Related and Claudin-Low Breast Cancer: Blood Relatives or Stepsisters.

Madaras L, Balint N, Gyorffy B, Tokes AM, Barshack I, Yosepovich A, Friedman E, Paluch-Shimon S, Zippel D, Baghy K, Timar J, Kovalszky I, Kulka J, Szasz AM.

Pathobiology. 2016;83(1):1-12. doi: 10.1159/000439135. Epub 2015 Nov 14.

39.

Evaluation of p40 as a Myoepithelial Marker in Different Breast Lesions.

Kővári B, Szász AM, Kulka J, Marušić Z, Šarčević B, Tiszlavicz L, Cserni G.

Pathobiology. 2015 Sep;82(3-4):166-71. doi: 10.1159/000375127. Epub 2015 Aug 31.

40.

[Occurrence, intratumoral heterogeneity, prognostic and predictive potential of microsatellite instability following surgical resection of primary colorectal carcinomas and corresponding liver metastases].

Ágoston EI, Baranyai Z, Dede K, Bodoky G, Kulka J, Bursics A, Harsányi L, Szász AM.

Orv Hetil. 2015 Sep 6;156(36):1460-71. doi: 10.1556/650.2015.30218. Hungarian.

PMID:
26320600
41.

Expression of miRNAs in adenoid cystic carcinomas of the breast and salivary glands.

Kiss O, Tőkés AM, Vranic S, Gatalica Z, Vass L, Udvarhelyi N, Szász AM, Kulka J.

Virchows Arch. 2015 Nov;467(5):551-62. doi: 10.1007/s00428-015-1827-3. Epub 2015 Aug 21.

PMID:
26293217
42.

Complexity of Response Evaluation During Primary Systemic Therapy of Breast Cancer: Scoring Systems and Beyond-Preliminary Results.

Tőkés T, Szentmártoni G, Torgyík L, Somlai K, Kulka J, Lengyel Z, Györke T, Dank M.

Anticancer Res. 2015 Sep;35(9):5063-72.

PMID:
26254408
43.

Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study.

Tőkés T, Szentmártoni G, Torgyík L, Kajáry K, Lengyel Z, Györke T, Molnár BÁ, Tőkés AM, Kulka J, Dank M.

Croat Med J. 2015 Apr;56(2):128-38.

44.

Primary systemic therapy for breast cancer: Does the patient's involvement in decision-making create a new future?

Tőkés T, Torgyík L, Szentmártoni G, Somlai K, Tóth A, Kulka J, Dank M.

Patient Educ Couns. 2015 Jun;98(6):695-703. doi: 10.1016/j.pec.2015.02.012. Epub 2015 Feb 25. Review.

PMID:
25749023
45.

Expression of proliferation markers Ki67, cyclin A, geminin and aurora-kinase A in primary breast carcinomas and corresponding distant metastases.

Tökés AM, Szász AM, Geszti F, Lukács LV, Kenessey I, Turányi E, Meggyesházi N, Molnár IA, Fillinger J, Soltész I, Bálint K, Hanzély Z, Arató G, Szendröi M, Kulka J.

J Clin Pathol. 2015 Apr;68(4):274-82. doi: 10.1136/jclinpath-2014-202607. Epub 2015 Jan 16.

PMID:
25595275
46.

[Is it radical enough? Transanal endoscopic microsurgery for the treatment of rectal neoplasia -- clinicopathological viewpoint].

Ács B, Szász AM, Kulka J, Harsányi L, Zaránd A.

Magy Seb. 2014 Dec;67(6):329-33. doi: 10.1556/MaSeb.67.2014.6.2. Hungarian.

PMID:
25500639
47.

Basaloid carcinoma of the pancreas--clinicopathological presentation and oncogenetic snapshot of a rare entity.

Szasz AM, Szirtes I, Tihanyi B, Barkaszi B, Baranyai Z, Tihanyi T, Harsanyi L, Timar J, Kulka J.

Virchows Arch. 2015 Feb;466(2):237-41. doi: 10.1007/s00428-014-1662-y. Epub 2014 Nov 29.

PMID:
25432630
48.

Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study.

Balmativola D, Marchiò C, Maule M, Chiusa L, Annaratone L, Maletta F, Montemurro F, Kulka J, Figueiredo P, Varga Z, Liepniece-Karele I, Cserni G, Arkoumani E, Amendoeira I, Callagy G, Reiner-Concin A, Cordoba A, Bianchi S, Decker T, Gläser D, Focke C, van Diest P, Grabau D, Lips E, Wesseling J, Arisio R, Medico E, Wells C, Sapino A.

Breast Cancer Res Treat. 2014 Dec;148(3):511-23. doi: 10.1007/s10549-014-3192-3. Epub 2014 Nov 14.

49.

Reponse to: comment on, 'Tumour-stroma ratio (TSR) in oestrogen-positive breast cancer patients'.

Downey CL, Simpkins SA, Holliday DL, Jones JL, Jordan LB, Kulka J, Hanby AM, Speirs V.

Br J Cancer. 2015 May 26;112(11):1833-4. doi: 10.1038/bjc.2014.571. Epub 2014 Nov 13. No abstract available.

50.

Correlations of differentially expressed gap junction connexins Cx26, Cx30, Cx32, Cx43 and Cx46 with breast cancer progression and prognosis.

Teleki I, Szasz AM, Maros ME, Gyorffy B, Kulka J, Meggyeshazi N, Kiszner G, Balla P, Samu A, Krenacs T.

PLoS One. 2014 Nov 10;9(11):e112541. doi: 10.1371/journal.pone.0112541. eCollection 2014.

Supplemental Content

Support Center